Speaker Profile
Ph.D., Vice President, Business Development, Biodesix
Biography
Matthew Pink has over 14 years of experience in the pharma and diagnostics industries. He leads the biopharma services division at Biodesix, Inc. He previously served as Director of Business Development at CSL Behring followed by U.S. Director of Research External Innovation. Matthew has a B.S. in Biology from the University of Wisconsin-Madison and a Ph.D. in Neuroscience from the University of Colorado.
Talk
Guiding Therapeutic Development with Ultrasensitive, Cost-effective ctDNA Monitoring
Trends in the use of ctDNA in clinical trials to support refinement of dosage and surrogate intermediate endpointsTechnology features to consider for longitudinal ctDNA monitoring Benefits of Droplet Digital PCR (ddPCR) in prospective and retrospective clinical trials
Clinical Dx Showcase:
Biodesix
At Biodesix, we are your dedicated partner throughout the entire diagnostic journey, from biomarker discovery to assay development, verification, and validation to clinical trial sample testing through to test commercialization. We offer a comprehensive suite of services to turn your therapeutic development into tangible results.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
